Back to Search
Start Over
Safety of low-dose subcutaneous recombinant interleukin-2: systematic review and meta-analysis of randomized controlled trials
- Source :
- Scientific Reports, Vol 9, Iss 1, Pp 1-9 (2019), Scientific Reports
- Publication Year :
- 2019
- Publisher :
- Springer Science and Business Media LLC, 2019.
-
Abstract
- Standard-dose intravenous recombinant interleukin-2 (rIL-2) is indicated for the treatment of some subtypes of cancer; however, severe adverse events, including venous thromboembolism (VTE), may complicate its administration. Low-dose subcutaneous rIL-2 is being studied for the management of immune-mediated diseases, since it can modulate the immunological response by specifically targeting T regulatory (Treg) cells; importantly, it is supposed to cause fewer or no complications. In this systematic review and meta-analysis of phase II-III randomized controlled trials (RCTs), we investigated the safety of low-dose (
- Subjects :
- 0301 basic medicine
medicine.medical_specialty
Injections, Subcutaneous
MEDLINE
lcsh:Medicine
chemical and pharmacologic phenomena
Placebo
Article
law.invention
03 medical and health sciences
Clinical Trials, Phase II as Topic
0302 clinical medicine
Randomized controlled trial
law
Neoplasms
Internal medicine
Recombinant interleukin-2
Humans
Medicine
Drug safety
lcsh:Science
Adverse effect
Randomized Controlled Trials as Topic
Multidisciplinary
Dose-Response Relationship, Drug
Adverse effects
business.industry
lcsh:R
Absolute risk reduction
Cancer
medicine.disease
Recombinant Proteins
Treatment Outcome
030104 developmental biology
Clinical Trials, Phase III as Topic
Immune System Diseases
Meta-analysis
Interleukin-2
lcsh:Q
business
030217 neurology & neurosurgery
Subjects
Details
- ISSN :
- 20452322
- Volume :
- 9
- Database :
- OpenAIRE
- Journal :
- Scientific Reports
- Accession number :
- edsair.doi.dedup.....80f73993c209a83e0e15bac1d30c1ca5